Bassi F, Bartolini O, Neri A S, Gheri R G, Bucciantini S, Cheli D, Bruni V
Dipartimento di Fisiopatologia Clinica, University of Firenze, Italy.
J Endocrinol Invest. 1994 Nov;17(10):793-7. doi: 10.1007/BF03347778.
It may be possible to recognize different forms of precocious puberty at the first evaluation. In a group of 26 sexually precocious girls we used Bayley-Pinneau predicted adult height (P.A.H.) to discriminate patients with 'poor' or 'good' height prognosis. Patients with evidence of impaired height prognosis (P.A.H. < -1 SDS) (Group 1) were immediately treated with LH-RH analogs, while patients with unimpaired height prognosis (P.A.H. > -1 SDS) (Group 2) were followed without therapy. Two yr of treatment significantly improved P.A.H. in Group 1 patients, from a mean of -1.68 +/- 0.4 to a mean of -0.57 +/- 0.6 (SDS) (p < 0.01). After the 2 yr observation period, Group 2 patients showed no significant variation of P.A.H. (from a mean of 0.45 +/- 0.8 to a mean of 0.33 +/- 0.6). The retrospective analysis of the growth pattern changes in the two Groups seems to indicate that LH-RH agonist treatment improves height potential in girls with initial poor height prognosis and that girls with initial good height prognosis maintain an unimpaired growth potential.
在初次评估时，或许有可能识别出不同形式的性早熟。在一组26例性早熟女孩中，我们使用贝利-平诺预测成人身高（P.A.H.）来区分身高预后“差”或“好”的患者。有身高预后受损证据（P.A.H. < -1 SDS）的患者（第1组）立即接受促性腺激素释放激素（LH-RH）类似物治疗，而身高预后未受损（P.A.H. > -1 SDS）的患者（第2组）则不接受治疗进行随访。两年的治疗显著改善了第1组患者的P.A.H.，从平均-1.68 ± 0.4提高到平均-0.57 ± 0.6（SDS）（p < 0.01）。经过2年的观察期，第2组患者的P.A.H.没有显著变化（从平均0.45 ± 0.8到平均0.33 ± 0.6）。对两组生长模式变化的回顾性分析似乎表明，LH-RH激动剂治疗可改善初始身高预后较差女孩的身高潜力，而初始身高预后良好的女孩保持未受损的生长潜力。
